Swiss National Bank Invests $671,000 in Personalis, Inc. $PSNL

Swiss National Bank acquired a new position in Personalis, Inc. (NASDAQ:PSNL) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 105,400 shares of the company’s stock, valued at approximately $671,000.

Several other large investors have also modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its stake in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of Personalis in the second quarter worth approximately $30,000. International Assets Investment Management LLC bought a new stake in shares of Personalis during the 4th quarter worth approximately $31,000. BNP Paribas Financial Markets lifted its stake in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares during the last quarter. Finally, Focus Partners Wealth purchased a new position in Personalis during the 1st quarter valued at $47,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Stock Performance

Shares of NASDAQ PSNL opened at $12.66 on Friday. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -12.41 and a beta of 2.24. The stock has a 50 day moving average price of $12.02 and a 200 day moving average price of $9.19. Personalis, Inc. has a 52-week low of $3.84 and a 52-week high of $16.39.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The firm had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. Analysts forecast that Personalis, Inc. will post -1.07 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on PSNL shares. Needham & Company LLC downgraded Personalis from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. BTIG Research lifted their target price on Personalis from $11.00 to $16.25 and gave the stock a “buy” rating in a research report on Monday, July 20th. TD Cowen reissued a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Morgan Stanley upped their price target on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Finally, Zacks Research downgraded shares of Personalis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $14.25.

Insider Buying and Selling at Personalis

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the sale, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $3,558,668.88. This represents a 29.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $14.00, for a total value of $69,748.00. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. The trade was a 2.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 435,032 shares of company stock valued at $5,599,929 over the last quarter. Company insiders own 4.20% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.